Not Baseline Atrial Fibrillation but New-Onset Atrial Fibrillation and the Loss of Left Atrial Function Are Essential for Predicting Poor Outcomes in Non-ischemic Cardiomyopathy

Mana Okune¹, Masakazu Yasuda¹, Naoko Soejima¹, Kazuyoshi Kakehi¹, Takayuki Kawamura¹, Takashi Kurita¹, Gaku Nakazawa¹ and Yoshitaka Iwanaga¹,²*

¹ Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Kindai University, Osakasayama, Japan,
² Department of Medical and Health Information Management, National Cerebral and Cardiovascular Center, Suita, Japan

Aims: The clinical impact of the type of atrial fibrillation (AF) has not been completely elucidated in non-ischemic cardiomyopathy (NICM). Although the structure and function of the left atrium (LA) provide prognostic information in patients with heart failure, the relationship of the AF type with LA structure and function in NICM is unclear.

Methods: Consecutive patients with NICM who underwent cardiac magnetic resonance were evaluated and followed. Multivariable Cox regression models were used to estimate hazard ratios (HRs) for major adverse cardiovascular events (MACE) related to the AF type, such as paroxysmal AF, chronic AF, and new-onset AF (NOAF).

Results: Among 625 patients with NICM (mean age, 64.4 ± 14.2 years; women, 39.7%), 133 had a history of AF at baseline; of these, 60 had paroxysmal AF. Each baseline AF type was associated with higher LA volume and lower LA emptying fraction but not with an increased incidence of MACE (p = 0.245). New-onset AF developed in 5.9% of patients with sinus rhythm over a median follow-up period of 609 days, and maximum LA volume was a strong and independent predictor (p < 0.001, area under the ROC curve (AUC): 0.795). Maximum LA volume was superior to LA emptying fraction and B-type natriuretic peptide (AUC: 0.683 and 0.680, respectively). The use of β-blocker and the age of the patient were associated with the incidence of NOAF (HR: 0.37, 95% CI: 0.16–0.84 and HR: 1.05, 95% CI: 1.01–1.09, respectively). Kaplan–Meier analysis showed that patients with NOAF had a higher incidence of MACE than those with sinus rhythm or baseline AF (p = 0.002). NOAF and LA emptying fraction were independent predictors of MACE (HR: 2.28, 95% CI: 1.20–3.97 and HR: 0.98, 95% CI: 0.96–0.99, respectively) after adjusting for age, sex, body mass index, and diagnosis.

Conclusions: Paroxysmal and chronic AF in patients with NICM were not associated with an increased incidence of MACE despite their association with LA volume and
INTRODUCTION

Atrial fibrillation (AF) results in atrial enlargement and is a major arrhythmia associated with heart failure (HF). Hypertension, diabetes, obesity, smoking, and coronary artery disease have been scored as risk factors for AF development (1). AF is classified as paroxysmal or chronic (persistent or permanent) depending on the duration, and among these types, newly developed AF events are attracting attention. A recent study reported that new-onset AF (NOAF) was associated with poor prognosis in acute coronary syndrome (2). Additionally, among patients with HF, NOAF had a significant prognostic impact (3). However, previous studies reported conflicting findings regarding whether baseline AF is an independent predictor of poor prognosis in patients with HF (4). Although NOAF was found to have a significant association with cardiovascular (CV) events in a broad cohort of patients with HF, the clinical impact of NOAF remains unclear in a subcohort of patients with HF, particularly in non-ischemic cardiomyopathy (NICM). NICM, which leads to a decline in cardiac function, results in HF and severe arrhythmic events (5, 6). The relationship of these outcomes with AF types has not been fully elucidated in NICM, and although several factors have been reported, novel predictive factors for the onset of AF need to be explored to prevent the onset of NOAF.

Left atrial (LA) enlargement is a strong predictor of cardiovascular events in the general population and patients with AF or HF (7, 8). A detailed assessment of the structure and function of LA using echocardiography or cardiac magnetic resonance (CMR) provides prognostic information about incident AF, HF onset, and stroke (9, 10). However, the relationship of AF type with LA structure and function in NICM has not been completely examined. In this study, we evaluated the clinical impact of baseline AF and NOAF in patients across a broad spectrum of NICM who underwent CMR examination. We performed a detailed CMR analysis to assess the relationship between LA volume/function and AF type and attempted to elucidate its prognostic potential.

METHODS

Study Protocol

This was a single-center study in which consecutive patients with cardiomyopathy referred for cardiac magnetic resonance (CMR) were enrolled between February 2008 and December 2018 at Kindai Hospital (Osakasayama, Japan). The referral reason for CMR was to diagnose or evaluate the cardiomyopathy initially, and the patients were in a stable condition. Patients with significant coronary artery disease (significant stenosis of ≥50% of a major coronary artery and history of myocardial infarction) were ruled out by coronary angiography, computed tomography, or CMR (11). NICM was then defined as cardiomyopathy excluding significant primary valve disease, congenital heart disease, acute myocarditis, arrhythmogenic right ventricular cardiomyopathy, and postchemotherapeutic left ventricular dysfunction (12).

The further etiological diagnosis was made based on the following criteria: left ventricular non-compaction (LVNC); the ratio of non-compact ed to compacted myocardi um in end-diastole of ≥2.3 by CMR (13); dilated cardiomyopathy (DCM); LV dysfunction and dilatation in the absence of coronary artery disease and specific heart muscle diseases (14); hypertrophic cardiomyopathy (HCM); LV hypertrophy of ≥15 mm and asymmetric/focal hypertrophy in the absence of another disease that could account for the hypertrophy (15); cardiac sarcoidosis (CS); fulfilling the guidelines published in 2016 by the Japanese Circulation Society or the characteristic manifestations and positive findings of echocardiography, 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET), or CMR with or without extra CS after exclusion from other known cardiac diseases (16); cardiac amyloidosis (CA); and histological confirmation of amyloidosis by tissue biopsies. The workup at the initial diagnosis included an electrocardiogram (ECG) and echocardiography. The LA diameter and degree of mitral regurgitation (MR) were also assessed. MR was considered to be significant if at least grades 2 of 4 were obtained. The plasma B-type natriuretic peptide (BNP) and serum creatinine levels were measured for clinical purposes. The estimated glomerular filtration rate (eGFR) was calculated using an equation specific to the Japanese population: eGFR = 194 × (serum creatinine) – 1.094 × (age) – 0.287 × (0.739 for women).

Paroxysmal AF (PAF) was defined as self-terminating or being cardioverted within 7 days of onset. Chronic AF (CAF), including persistent or permanent AF, lasted >7 days. NOAF was defined if AF was diagnosed or documented during follow-up by the attending physicians among patients without baseline AF (no history of AF and no AF in the baseline ECG).

CMR Image Acquisition and Analysis

Cardiac magnetic resonance was performed using a 1.5 T scanner (Intera 1.5T; Philips Medical Systems, the Netherlands), according to a standardized protocol. Cine images were acquired with a steady-state free-precession breath-hold sequence (SSFP) in contiguous short-axis slices (10 mm, no gap) from the atrioventricular ring to the apex. Image analysis was performed using commercially available workstations (Aze Virtual Place; Aze, Japan). Endocardial and epicardial contours on short-axis SSFP images were manually delineated on end-diastolic and end-systolic short-axis slices in LV. The summation disk method...
was used to calculate end-diastolic volume, end-systolic volume, ejection fraction (EF), and masses (17).

To assess LA volume and function, the endocardial borders in two- and four-chamber cine images were contoured carefully, excluding the pulmonary veins and LA appendage. LA volume was calculated based on the biplane area-length method, i.e., LA volume $= (0.848 \times \text{area}_{4\text{-ch}} \times \text{area}_{2\text{-ch}})/(\text{length}_{4\text{-ch}} + \text{length}_{2\text{-ch}})/2$, based on a previous study (18). Maximum LA volume ($V_{\text{max}}$: LA volume at end-systole, immediately before mitral valve opening), minimum LA volume ($V_{\text{min}}$: LA volume at the onset of the P-wave on ECG) were defined, and LA emptying fraction $=[(V_{\text{max}}-V_{\text{min}})/V_{\text{max}} \times 100\%]$, LA passive emptying fraction $=[(V_{\text{max}}-V_{\text{preA}})/V_{\text{max}} \times 100\%]$, and LA active emptying fraction $=[(V_{\text{preA}}-V_{\text{min}})/V_{\text{preA}} \times 100\%]$ were calculated (Supplementary Figure 1).

**Clinical Follow-Up**

Long-term clinical follow-up, through 2,500 days from CMR testing, was accomplished through a patient-completed questionnaire, telephone interviews, or via chart reviews. The following events were recorded: combined major adverse cardiac events (MACE), such as CV mortality, hospitalization for worsening HF, and severe arrhythmia; and all-cause mortality, including the cause of death. CV death was defined as sudden death and death attributed to CV causes, such as fatal myocardial infarction, pump failure, stroke, and severe arrhythmia. Hospitalization for worsening HF was defined as an unexpected presentation to an acute-care facility requiring hospitalization with exacerbation of HF. Severe arrhythmia was defined as sustained ventricular tachycardia/fibrillation, including appropriate implantable cardioverter-defibrillator discharge. All events were based on the clinical diagnosis; however, to validate these events, the medical records were reviewed by us or the physician in charge. They were reviewed independently by two cardiologists (MY and TK), and disagreements were forwarded to a senior cardiologist (YT) for further review.

**Statistical Analysis**

The student's $t$-test was performed for comparisons among groups as part of the univariate analysis for continuous variables. Pearson $\chi^2$ or Fisher's exact test was used to assessing differences in categorical variables using JMP version 14.0 software (SAS Institute, Cary, NC, USA). Furthermore, multiple logistic regression analysis was used to explore the relationship of CMR parameters and BNP level with NOAF. The cutoff levels were different between the CAF and PAF groups: proportion, lower eGFR, frequent NYHA class II, and frequent medications, including diuretics and anticoagulants, were administered more frequently than that of sinus rhythm (SR). Only patients with CAF had older age, lower female proportion, lower eGFR, frequent NYHA class $\geq$ II, and frequent medications, including $\beta$-blockers and calcium channel blockers, compared with those with SR. Increased resting HR, increased LA diameter, and frequent moderate or greater MR were also observed only in the patients. The following characteristics were different between the CAF and PAF groups: proportion of women; eGFR; NYHA class $\geq$ II; medications, including diuretics, anticoagulants, and amiodarone; resting HR; LA diameter; and frequent moderate or greater MR. Regarding the etiological diagnosis of NICM, DCM was most frequently diagnosed in any group, followed by HCM. Patients with DCM had a higher frequency of CAF. Left ventricular ejection fraction was decreased only in the CAF group, and no significant differences were found in other LV parameters among the three groups. Significant differences in LA parameters were found in the three groups. The CAF group showed the largest LA volumes and the lowest LA empty fractions; in contrast, the SR group showed the smallest LA volumes and the highest LA empty fractions.

We followed up 492 patients with baseline SR (cohort 2), and 29 (5.9%) patients developed NOAF (NOAF group) over a median follow-up period of 609 days. Table 2 presents...
the baseline clinical characteristics of the patients in Cohort 2. Significant differences were observed only in BNP levels and LA diameter. Although no significant difference was observed in LV parameters, the NOAF group showed higher LA volumes and lower LA emptying fractions than the SR group. The LA Vmax of the NOAF group was similar to that of the baseline CAF group or PAF group. The LA emptying fraction of the NOAF group was similar to that of the baseline PAF group and higher than that of the baseline CAF group.

Among the cohorts categorized according to the etiological diagnosis of NICM, there was no difference in LA Vmax, but CAF group.

### Table 1: Clinical characteristics and CMR findings according to baseline rhythm in cohort 1.

|                        | Total patients (n = 625) | Sinus rhythm (n = 492) | CAF (n = 73) | PAF (n = 60) | P-value |
|------------------------|--------------------------|------------------------|--------------|--------------|---------|
| Age, years             | 64.4 ± 14.2              | 63.1 ± 14.6            | 70.0 ± 10.0a | 67.3 ± 12.6  | <0.001  |
| Female                 | 248 (39.7%)              | 204 (41.5%)            | 19 (25.7%)a  | 25 (41.7%)a  | 0.040   |
| Body mass index, kg/m² | 23.0 ± 4.3               | 23.1 ± 4.4             | 22.8 ± 4.0   | 22.9 ± 4.1   | 0.851   |
| eGFR, mL/min/1.73 m²   | 77.5 ± 25.7              | 79.4 ± 26.0            | 65.6 ± 18.5a | 76.7 ± 26.5a | <0.001  |
| log BNP                | 4.7 ± 1.3                | 4.5 ± 1.4              | 5.4 ± 0.9a   | 5.3 ± 1.1a   | 0.001   |
| NYHA classification ≥II| 246 (39.4%)              | 170 (34.6%)            | 48 (65.8%)a  | 28 (46.7%)a  | <0.001  |
| Etiological diagnosis  |                          |                        |              |              |         |
| LVNC                   | 51 (8.1%)                | 46 (9.4%)              | 1 (1.4%)     | 4 (6.7%)     |         |
| Dilated cardiomyopathy | 234 (37.4%)              | 174 (35.4%)            | 41 (56.2%)   | 19 (31.7%)   |         |
| Hypertrophic cardiomyopathy | 198 (31.7%)           | 159 (32.3%)            | 19 (26.0%)   | 20 (33.3%)   |         |
| Cardiac sarcoidosis    | 124 (19.8%)              | 100 (20.3%)            | 12 (16.4%)   | 12 (20.0%)   |         |
| Cardiac amyloidosis    | 18 (2.9%)                | 13 (2.6%)              | 0 (0.0%)     | 5 (8.3%)     |         |
| Medication             |                          |                        |              |              |         |
| ACE-I/ARB              | 399 (63.8%)              | 302 (61.4%)            | 53 (72.6%)   | 44 (73.3%)   | 0.044   |
| β-Blocker              | 384 (61.4%)              | 288 (58.5%)            | 57 (78.1%)a  | 39 (65.0%)   | 0.004   |
| Calcium channel blocker| 176 (28.2%)              | 127 (25.8%)            | 28 (38.4%)a  | 21 (35.0%)   | 0.045   |
| Diuretics              | 250 (40.0%)              | 159 (32.3%)            | 58 (79.5%)a  | 33 (55.0%)aT | <0.001  |
| MRA                    | 129 (20.6%)              | 91 (18.5%)             | 23 (31.5%)a  | 15 (25.0%)   | 0.033   |
| Anticoagulant          | 148 (23.7%)              | 27 (5.5%)              | 73 (100%)a   | 48 (80.0%)aT | <0.001  |
| Amiodarone             | 22 (3.5%)                | 13 (2.6%)              | 1 (1.4%)     | 8 (13.3%)T   | <0.001  |
| Echo parameters        |                          |                        |              |              |         |
| Heart rate, beats/min  | 69.8 ± 15.6              | 68.3 ± 14.0            | 79.1 ± 18.9a | 70.2 ± 18.9a | <0.001  |
| Left atrial diameter, mm | 41.7 ± 7.4               | 40.4 ± 6.6             | 49.8 ± 8.0a  | 42.2 ± 6.5T  | <0.001  |
| CMR parameters         |                          |                        |              |              |         |
| Left ventricle         |                          |                        |              |              |         |
| End-diastolic volume, mL| 176.0 ± 72.3             | 175.3 ± 71.7           | 178.6 ± 69.7 | 178.2 ± 80.7 | 0.908   |
| End-systolic volume, mL| 115.6 ± 72.9             | 113.2 ± 72.3           | 130.2 ± 69.1 | 117.3 ± 80.8 | 0.174   |
| Ejection fraction, %   | 38.7 ± 15.9              | 40.0 ± 15.7            | 30.3 ± 15.2a | 38.8 ± 15.1  | <0.001  |
| Mass, g                | 115.0 ± 44.3             | 116.3 ± 45.6           | 108.4 ± 38.4 | 112.8 ± 40.8 | 0.335   |
| Left atrium            |                          |                        |              |              |         |
| Vmax, mL               | 93.2 ± 44.6              | 83.5 ± 33.6            | 143.7 ± 68.0a| 110.7 ± 41.5aT| <0.001  |
| Vmax index, mL/m²      | 57.6 ± 27.7              | 51.5 ± 20.7            | 88.3 ± 42.6a | 69.6 ± 26.4T | <0.001  |
| Vmin, mL               | 63.1 ± 41.5              | 52.3 ± 29.1            | 121.1 ± 58.3a| 80.8 ± 30.9aT| <0.001  |
| Vmin index, mL/m²      | 39.0 ± 25.8              | 32.3 ± 18.0            | 74.6 ± 36.7a | 50.9 ± 24.6aT| <0.001  |
| Emptying fraction, %   | 35.9 ± 13.9              | 39.7 ± 11.9            | 15.9 ± 5.8a  | 29.1 ± 13.0T | <0.001  |
| Passive emptying fraction, % | 16.6 ± 7.8              | 17.5 ± 8.1            | 12.3 ± 5.2a  | 14.2 ± 6.2a  | <0.001  |
| Active emptying fraction, % | 23.4 ± 13.7              | 27.0 ± 12.0           | 4.0 ± 4.1a   | 17.7 ± 12.7T | <0.001  |

Values are the mean ± SD or n (%). aP < 0.05 vs. sinus rhythm; T P < 0.05 vs. CAF.
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; CAF, chronic atrial fibrillation; CMR, cardiac magnetic resonance; eGFR, estimated glomerular filtration rate; LVNC, left ventricle non-compaction; MR, mitral regurgitation; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; PAF, paroxysmal atrial fibrillation; Vmax, volume at maximum; Vmin, volume at minimum.
there was a significant difference in the LA emptying fraction (Supplementary Table 1). CA was significantly decreased compared with other diagnoses ($p < 0.001$ for all), and CS was significantly increased compared with DCM ($p = 0.001$). Nevertheless, the prevalence of baseline CAF/PAF and NOAF events did not differ among the etiologies ($p = 0.081$ and $0.805$, respectively).

### Clinical Determinants of NOAF

Univariate analysis in Cohort 2 showed that age, log BNP levels, LA volumes, LA emptying fraction, and LA passive emptying fraction were associated with the development of NOAF (Supplementary Table 2). In contrast, LV EF and etiological diagnosis did not show an association. The ROC curve analysis showed that LA Vmax showed the best predictive performance
of NOAF, with an area under the ROC curve (AUC) of 0.795 (95% CI, 0.691–0.898) (Figure 1A). The optimal cutoff value of LA Vmax was 121.6 ml (sensitivity of 62.1% and specificity of 90.7%). When baseline LA Vmax, LA emptying fraction, or BNP levels were divided by the median value, patients with larger LA Vmax, lower LA emptying fraction, or higher BNP level developed NOAF more in cohort 2 (Figure 1B). Multivariate Cox proportional risk analysis showed that age and β-blocker use in addition to LA Vmax were independent predictors of NOAF (Table 3A). Older patients with higher LA Vmax had a higher risk of developing NOAF than younger patients with lower LA Vmax (odds ratio, 15.64; 95% CI, 2.03–120.30) (Supplementary Figure 3). β-Blocker use was associated with a low incidence of NOAF in the groups with higher LA Vmax (Supplementary Figure 4).

Clinical Outcomes and the Relationship With LA Geometry/Function

Kaplan–Meier analysis in cohort 1 revealed no significant differences in both MACE and all-cause death among baseline rhythms (Figure 2A). Each type of AF at baseline was associated with LA volume and function but not with MACE and all-cause death. Patients with baseline CAF and PAF showed more frequent hospitalization for HF (p = 0.005; Supplementary Table 3; Supplementary Figure 5A). Conversely, Kaplan–Meier analysis in cohort 2 revealed that NOAF and lower LA emptying fraction (≤39.8%) led to a poor prognosis of both MACE and all-cause death (Figure 2B). Moreover, patients with NOAF had MACE, all-cause death, and hospitalization for HF more frequently than those with any type of baseline AF.

Univariate analysis of MACE revealed significant associations of MACE with variables such as age, body mass index, diagnosis; NOAF; NYHA ≥2; log BNP level; and β-blocker, mineralocorticoid receptor antagonist and diuretic use, in clinical characteristics, and LV EF, LA Vmin, and LA emptying fraction in CMR findings (Supplementary Table 2). In the Kaplan–Meier analysis stratified according to diagnosis, only CA showed poor prognosis with a shorter follow-up period (Supplementary Table 1; Supplementary Figure 5B). Multivariate Cox proportional risk analysis revealed that NOAF and LA emptying fraction were independent predictors of MACE (HR, 2.28; 95% CI, 1.20–3.97 and HR, 0.98; 95% CI, 0.96–0.99; respectively) after adjusting for age, sex, body mass index, and the diagnosis (Table 3B). NOAF was also an independent predictor of all-cause death after adjusting for age, sex, body mass index, and diagnosis (HR, 2.68; 95% CI, 1.08–5.70); however, LA emptying fraction was not associated with an all-cause death (Table 3C). LV EF was not associated with both MACE and all-cause death (Model 2), and log BNP was independently associated with both MACE and all-cause death (Model 3).
### TABLE 3 Multivariate cox proportional hazards analysis.

|                      | Model 1               | Model 2               | Model 3               |
|----------------------|-----------------------|-----------------------|-----------------------|
| **Variable**         | HR (95% CI)           | P-value               | HR (95% CI)           | P-value               | HR (95% CI)           | P-value               |
| (A)  
For the incidence of NOAF |                       |                       |                       |                       |                       |                       |
| LA Vmax (mL)         | 1.03 (1.02–1.03)      | <0.001                |                       |                       |                       |                       |
| LA emptying fraction (%) | 0.94 (0.91–0.97)   | <0.001                | 1.71 (1.25–2.38)      | <0.001                |                       |                       |
| log BNP              |                       |                       |                       |                       |                       |                       |
| Age (years)          | 1.03 (1.01–1.09)      | 0.006                 | 1.03 (1.00–1.06)      | 0.041                 | 1.03 (1.00–1.06)      | 0.054                 |
| p-Blocker use        | 0.37 (0.16–0.84)      | 0.018                 | 0.44 (0.20–0.99)      | 0.047                 | 0.46 (0.21–1.01)      | 0.054                 |
| (B)  
For MACE         |                       |                       |                       |                       |                       |                       |
| NOAF                 | 2.28 (1.20–3.97)      | 0.014                 | 2.26 (1.19–3.95)      | 0.015                 | 2.05 (1.08–3.56)      | 0.029                 |
| LA emptying fraction (%) | 0.98 (0.96–0.99)   | 0.002                 | 0.98 (0.96–0.99)      | 0.005                 | 0.99 (0.87–1.00)      | 0.139                 |
| Age (years)          | 1.02 (1.00–1.04)      | 0.027                 | 1.02 (1.01–1.04)      | 0.007                 | 1.02 (1.00–1.04)      | 0.014                 |
| Sex (male/female)    | 1.32 (0.88–2.00)      | 0.183                 | 1.25 (0.84–1.88)      | 0.279                 | 1.36 (0.91–2.06)      | 0.129                 |
| Body mass index      | 0.90 (0.85–0.96)      | <0.001                | 0.90 (0.85–0.96)      | <0.001                | 0.92 (0.87–0.97)      | <0.001                |
| Diagnosis –          |                       |                       |                       |                       |                       |                       |
| LV ejection fraction (%) | 0.99 (0.98–1.00)   | 0.163                 |                       |                       |                       |                       |
| log BNP              |                       |                       |                       |                       |                       |                       |
| (C)  
For all-cause death |                       |                       |                       |                       |                       |                       |
| NOAF                 | 2.68 (1.06–5.70)      | 0.034                 | 2.71 (1.09–5.85)      | 0.034                 | 2.59 (1.08–3.73)      | 0.022                 |
| LA emptying fraction (%) | 0.99 (0.97–1.02)   | 0.557                 | 0.99 (0.97–1.01)      | 0.281                 | 1.00 (0.98–1.03)      | 0.671                 |
| Age (years)          | 1.04 (1.01–1.08)      | 0.001                 | 1.05 (1.03–1.09)      | <0.001                | 1.05 (1.02–1.09)      | <0.001                |
| Sex (male/female)    | 1.65 (0.89–3.18)      | 0.114                 | 1.80 (0.99–3.43)      | 0.055                 | 1.97 (1.08–3.73)      | 0.031                 |
| Body mass index      | 0.89 (0.82–0.97)      | 0.006                 | 0.89 (0.82–0.96)      | 0.002                 | 0.92 (0.85–1.00)      | 0.037                 |
| Diagnosis –          |                       | <0.001                |                       |                       |                       |                       |
| LV ejection fraction (%) | 1.00 (0.97–1.01)   | 0.657                 |                       |                       |                       |                       |
| log BNP              |                       |                       |                       |                       |                       |                       |

BNP, B-type natriuretic peptide; CI, confidence interval; HR, hazard ratio; LA, left atrium; LV, left ventricle; MACE, major adverse cardiac events; NOAF, new-onset atrial fibrillation.

### DISCUSSION

Atrial fibrillation and HF frequently coexist, and they are closely interrelated, with each disease predisposing to the other (3). In this study, the relationship of AF type with a wide spectrum of NICM, including LVNC, HCM, DCM, CS, and CA, was explored. Patients with prevalent AF had higher age and increased BNP levels and were more symptomatic. Moreover, they took medications such as diuretics and anticoagulants more frequently. Although whether AF is truly independently associated with poor outcomes in HF remains controversial, and this study showed that baseline CAF and PAF were not associated with an increased incidence of MACE and mortality. Similarly, in HCM or CA, AF prevalence has been reported not to be a major contributor to HF morbidity or mortality (19, 20). In contrast, NOAF (incident AF) was associated with a higher risk of adverse outcomes, which are consistent with findings in other patient groups, including those with acute HF, chronic HF, acute coronary syndrome, and hemodialysis (21–23). In this study, we explored the clinical significance of NOAF in patients across a broad spectrum of NICM, which included a broad spectrum of LV functions. The incidence and prognostic impact of NOAF did not change across LV EF or the diseases groups (systolic or diastolic dysfunction dominant), suggesting that NOAF may be equally crucial in HF with both reduced and preserved EF. Additionally, patients with younger and lower NYHA were included, and they showed a better prognosis than those in previous studies of HF (24, 25). However, the incidence of NOAF was higher than that reported in previous studies. Factors other than HF severity may be associated with the incidence of NOAF. As shown in Tables 2, 3, increased LA volume or decreased LA function may be one of the most important factors. In particular, several events of HF hospitalization soon after the onset of new AF have been reported (24). Furthermore, in this study, MACE after NOAF occurred at a median of 38 days, calculated from the onset of NOAF, and HF hospitalization was the most frequent event among MACE, as shown in Supplementary Table 3. Although its reasons are unknown, NOAF may reflect the instability of HF more generally or it may...
A unique aspect of this study was the measurement of both BNP levels and LA function/geometry at baseline. This is essential because they are both valuable prognostic markers in HF (10, 25). Several studies demonstrated the association between BNP levels and NOAF in various conditions, including in the general population, in those with acute coronary syndrome, and the postoperative state (26, 27). Although baseline BNP level was a significant predictor of NOAF in this study, the association between them was not strong (AUC: 0.680). LA volume was a better predictor (AUC: 0.795) and was superior to BNP level in patients with NICM ($p = 0.016$). Structural and functional changes in LA have been reported to occur before AF development (9, 28), which this study also suggested in NICM. Recently, besides volumetric analysis, deformational (strain and strain rate) imaging with echocardiography has been used to evaluate LA function. Debonnaire et al. reported that both LA
volume and LA strain improved the prediction of NOAF in 242 patients with HCM (29). In addition, the use of β-blocker was negatively associated with the incidence of NOAF in this study. It may decrease the incidence of NOAF through the suppression of the activated sympathetic nervous system (30). It may be useful for further risk stratification to assess novel LA functional imaging, such as deformational (strain and strain rate) imaging or to explore the effect of medications in a cohort of NICM.

Atrial fibrillation progression is often characterized by progression from PAF to CAF. In this study, the deterioration of LA volume and function mirrored this progression; further deterioration of LA volume and function was observed from PAF to CAF. Because PAF or CAF was not associated with MACE or all-cause mortality in this cohort, the deterioration of LA volume and function observed in PAF and CAF did not suggest their direct relationship with the prognosis. However, the LA emptying fraction was associated with a poor prognosis independently of NOAF. A study of HF reported LA dysfunction as a major driver or mediator of clinical decompensation in HF (31). NOAF may be associated with HF decompensation, at least in part, through LA dysfunction; however, how LA dysfunction affects poor prognosis, including HF deterioration, remains unclear. Further studies are necessary to elucidate this for the improvement of clinical management.

This study had several limitations. First, patients across a broad spectrum of NICM at a single center were enrolled; the population may not be completely representative of the entire NICM population. The study population of each diagnosis and the number of patients with NOAF were relatively small, and the total number of events of these patients were also relatively few during follow-up. Any negative findings might be caused by low statistical power. Second, ambulatory serial ECG monitoring might have identified more incident AF than was reported. However, the incidence of NOAF was less or similar to those previously reported (24, 25). While echocardiographic assessment of LA morphology and function is challenging because of the posterior location and thin wall of the LA, CMR has been proposed as the reference method to measure atrial volumes. However, motion artifacts may occur in patients with arrhythmia, such as AF, and data acquisition can be challenging (32). Finally, the study cohort comprised patients who were referred for CMR examination. Thus, the generalizability of our findings might be limited, for example, to patients with severe renal impairment, severe HF, or previously implanted cardiac devices.

REFERENCES
1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. (1982) 306:1018–22. doi: 10.1056/NEJM19820429306107
2. Worme MD, Tan MK, Armstrong DWJ, Yan AT, Tan NS, Brieger D, et al. Previous and new onset atrial fibrillation and associated outcomes in acute coronary syndromes (from the Global Registry of Acute Coronary Events). Am J Cardiol. (2018) 122:944–51. doi: 10.1016/j.amjcard.2018.06.001

CONCLUSIONS
We analyzed 625 consecutive patients across a broad spectrum of NICM who underwent CMR examination, especially in terms of LA geometry and function. Baseline CAF and PAF were well-correlated with the deterioration of LA geometry and function, although they were not associated with an increased incidence of MACE and mortality. Additionally, 5.9% of the patients with baseline SR developed NOAF over a median follow-up of 609 days and were associated with poor prognosis independent of age, sex, body mass index, and diagnosis. LA Vmax showed better predictive performance than LA emptying fraction and BNP. In addition, older age and no β-blocker use were risk factors of NOAF. LA Vmax was not associated with prognosis; rather, the LA emptying fraction was associated with prognosis.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by Ethics Committee of Kindai University, Faculty of Medicine. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS
MO, MY, and YI: study concept, design, analysis, and interpretation of data. NS, TKa, MO, KK, and MY: data curation. TKu and GN: supervision. MO and MY: writing—original draft. YI: writing—review and editing. All authors contributed to the article and approved the submitted version.

FUNDING
This study was supported by grants from the Vehicle Racing Commemorative Foundation (YI).

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2021.781125/full#supplementary-material

3. Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation. (2016) 133:484–92. doi: 10.1161/CIRCULATIONAHA.115.018614
4. Hamaguchi S, Yokoshiki H, Kinugawa S, Tsuchihashi-Makaya M, Yokota T, Takeshita A, et al. Effects of atrial fibrillation on long-term outcomes in patients hospitalized for heart failure in Japan: a report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J. (2009) 73:2084–90. doi: 10.1253/circj.CJ-09-0316
5. Arbustini E, Narula N, Tavazzi L, Serio A, Grasso M, Favalli V, et al. The MOGE(S) classification of cardiomyopathy for clinicians. J Am Coll Cardiol. (2014) 64:304–18. doi: 10.1016/j.jacc.2014.05.027

6. Alba AC, Foroutan F, Duro Posada J, Battioni L, Schofield T, Alhussein M, et al. Implantable cardio defibrillator and mortality in non-ischaemic cardiomyopathy: an updated meta-analysis. Heart. (2018) 104:230–6. doi: 10.1136/heartjnl-2017-311430

7. Hedberg P, Selmerly J, Leppert J, Henriksen E. Long-term prognostic impact of left atrial volumes and emptying fraction in a community-based cohort. Heart. (2017) 103:687–93. doi: 10.1136/heartjnl-2016-310242

8. Seewöster T, Spampinato RA, Sommer P, Lindemann F, Jahnke C, et al. Right ventricular involvement is an important prognostic factor in dilated cardiomyopathy. Eur Heart J. (2015) 36:733–42. doi: 10.1093/eurheartj/ehu405

9. Okune et al. New-Onset AF and Left Atrium

10. Wilkins MR, Ommen SR, Longo S, Renfrow ML, Tran T, et al. CT and cardiac magnetic resonance imaging for the assessment of left atrial size. Circulation. (2015) 131:2420–36. doi: 10.1161/CIRCULATIONAHA.117.029267

11. Manchuelle A, Pontana F, De Groote P, Lebert P, Fertin M, Baijot M, et al. Left atrial structure and functional quantitation using cardiovascular magnetic resonance and multimodality tissue tracking: validation and reproducibility assessment. J Cardiovasc Magn. Res. (2015) 17:52. doi: 10.1186/s12968-015-0152-y

12. Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, et al. Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. (2017) 10:1–15. doi: 10.1016/j.jcmg.2018.07.015

13. Jacquier A, Thuny F, Jop B, Giorgi R, Cohen F, Gaubert JY, et al. Measurement of left atrial resonance−measured left atrial volume and function and incident atrial fibrillation: results from MESA (Multi-Ethnic Study of Atherosclerosis). Circ Cardiovasc Imaging. (2016) 9:e004299. doi: 10.1161/CIRCIMAGING.115.004299

14. Alba AC, Foroutan F, Duro Posada J, Battioni L, Schofield T, Alhussein M, et al. Increased left ventricular trabeculation is associated with increased b-type natriuretic peptide levels and impaired outcomes in nonischemic cardiomyopathy. Can J Cardiol. (2016) 32:518–26. doi: 10.1016/j.cjca.2016.09.012

15. Manchuelle A, Pontana F, De Groote P, Lebert P, Ferrin M, Rajot M, et al. Accuracy of cardiac magnetic resonance imaging to rule out significant coronary artery disease in patients with systolic heart failure of unknown aetiology: single-centre experience and comprehensive meta-analysis. Arch Cardiovasc Dis. (2018) 111:686–701. doi: 10.1016/j.acvd.2018.04.004

16. Kawamura T, Yasuda M, Okune M, Kakehi K, Kagioka Y, Nakamura T, et al. Increased left ventricular trabeculation is associated with increased b-type natriuretic peptide levels and impaired outcomes in nonischemic cardiomyopathy. Can J Cardiol. (2016) 32:518–26. doi: 10.1016/j.cjca.2016.09.012

17. Jacquier A, Thuny F, Jop B, Giorgi R, Cohen F, Gaubert JY, et al. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. Eur Heart J. (2010) 31:1098–104. doi: 10.1093/eurheartj/ehp595

18. Halliday BP, Baksy AJ, Gulati A, Ali A, Newsome S, Izgi C, et al. Outcome in dilated cardiomyopathy related to the extent, location, and pattern of late gadolinium enhancement. JACC Cardiovasc Imaging. (2019) 12:1645–55. doi: 10.1016/j.jcmg.2018.07.015

19. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the European Society of Cardiology Committee for practice guidelines. J Am Coll Cardiol. (2003) 42:1687–713. doi: 10.1016/S0195-668X(03)00479-2

20. Cheung CC, Roston TM, Andrade JG, Bennett MT, Davis MK. Arrhythmias in cardiac amyloidosis: challenges in risk stratification and treatment. Can J Cardiol. (2020) 36:416–23. doi: 10.1016/j.cjca.2019.11.039

21. Rivero-Ayerza M, Scholte Op Reimer W, Lenzen M, Theuns DA, Jordens L, et al. New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey, Eur Heart J. (2009) 29:1618–24. doi: 10.1093/eurheartj/ehn217

22. Lau DH, Huynt LT, Chew DP, Astley CM, Soman A, Sanders P. Prognostic impact of types of atrial fibrillation in acute coronary syndromes. Am J Cardiol. (2009) 104:1317–23. doi: 10.1016/j.amjcard.2009.06.055

23. Airy M, Chang TI, Ding VY, Goldstein BA, Bansal N, Niu J, et al. Risk profiles for acute health events after incident atrial fibrillation in patients with end-stage renal disease on hemodialysis. Nephrol Dial Transplant. (2018) 33:1590–7. doi: 10.1093/ndt/gfx301

24. Yamauchi T, Sakata Y, Miura M, Tadahi T, Sashihige R, Sato K, et al. Prognostic impact of new-onset atrial fibrillation in patients with chronic heart failure - a report from the CHART-2 study. Circ J. (2016) 80:157–67. doi: 10.1253/circj.CJ-15-0783

25. Mogensen UM, Hjund PS, Abraham WT, Desai AS, Dickstein K, Packer M, et al. Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. (2017) 70:2490–500. doi: 10.1016/j.jacc.2017.09.027

26. Sepehr Shamloo A, Bollmann A, Dages N, Hindricks G, Arya A. Natriuretic peptides: biomarkers for atrial fibrillation management. Clin Res Cardiol. (2020) 109:988–98. doi: 10.1007/s00392-020-01608-x

27. Simmers D, Potgieter D, Ryan L, Fahren R, Rodseth RN. The use of preoperative B-type natriuretic peptide as a predictor of atrial fibrillation after thoracic surgery: systematic review and meta-analysis. J Cardiothorac Vasc Anesth. (2015) 29:389–95. doi: 10.1053/j.jvca.2014.05.015

28. Modin D, Olsen FJ, Pedersen S, Jensen JS, Biering-Sørensen T. Measures of left atrial function predict incident atrial fibrillation in STEMI patients treated with primary percutaneous coronary intervention. Int J Cardiol. (2018) 263:1–6. doi: 10.1016/j.ijcard.2018.03.013

29. Debonnaire P, Joyce E, Hiemstra Y, Mertens BI, Atsma DE, Schali MJ, et al. Left atrial size and function in hypertrophic cardiomyopathy patients and risk of new-onset atrial fibrillation. Circ Arrhythm Electrophysiol. (2017) 10:e004502. doi: 10.1161/CIRCEP.116.004502

30. Carnagarin R, Kuchi MG, Ho JK, Matthews VB, Schlaich MP. Sympathetic nervous system activation and its modulation: role in atrial fibrillation. Front Neurosci. (2019) 12:1058. doi: 10.3389/fnins.2018.01058

31. Pellicori P, Zhang J, Lukaschuk E, Joseph AC, Bourantas CV, Loh H, et al. Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value. Eur Heart J. (2015) 36:733–42. doi: 10.1093/eurheartj/ehu405

32. Alfudhili K, Masci PG, Delacoste J, Ledoux JB, Berchier G, Denuet V, et al. Current artefacts in cardiac and chest magnetic resonance imaging: tips and tricks. Br J Radiol. (2016) 89:20150987. doi: 10.1259/bjr/20150987

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.